




Muhammad Samsoor Zarak
8.7K posts

@drzarak
Hem/Onc Fellowship Applicant | BMT fellow @Stanford | Ex- President National Resident Forum | Ex- Intern @HowardU | Ex- Polio Officer @WHOPakistan













Dr. Robert Negrin is being honored for a career of impact. His work translating research into patient care has earned him lifetime achievement awards, new leadership roles, and renewed NIH funding for the BMT-CT program at Stanford. Read more: medicine.stanford.edu/content/sm/med…

🚨 BREAKING: HOSPITALS DESTROYED IN JAMAICA 🚨 Medical facilities in Black River, Jamaica have reportedly been destroyed, according to a Jamaican Senator speaking to NBC. Amid Hurricane Melissa’s catastrophic landfall, emergency services are overwhelmed, and access to care is severely limited. 💔 Patients and medical staff are seeking shelter as power outages cripple operations. 🇯🇲 The situation is described as “beyond critical.” #Jamaica #HurricaneMelissa #BreakingNews #DisasterAlert #CaribbeanCrisis #PrayForJamaica #HurricaneUpdate #ClimateEmergency






Inna lillahi wa inna ilayhi raji’un. إِنَّا لِلَّٰهِ وَإِنَّا إِلَيْهِ رَاجِعُونَ. It is with heavy hearts that we announce the passing of Dr. Maryam Shaukat tonight. Although the liver had been secured for the transplant, Allah had other plans for her.



Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial @realbowtiedoc @crisbergerot @OncoAlert jnccn.org/view/journals/…







Results from a study open new avenues for discovering approaches to enhance the antitumor activity of CAR NK cell therapies against multiple cancer types via a comprehensive CRISPR discovery platform optimized for primary human NK cells. Read more: spr.ly/6018fxaTs @lab_rezvani #EndCancer


🚨 New CIBMTR Analysis: CD19 CAR T in Primary Mediastinal B-Cell Lymphoma (PMBCL) 🚨 CD19-directed CAR T-cell therapy is standard for high-risk R/R LBCL — but what about rare PMBCL? This multi-center registry study sheds light. 👥 Cohort: 135 adults, 66 centers 📅 Median age: 32 years 💉 28.9% received immune checkpoint inhibitor (ICI) prior to CAR T Efficacy: ✅ Overall response rate (ORR): 79% ✅ Complete response (CR): 67.7% 📅 2-year PFS: 58.6% (95% CI 49.7–67.3) 📅 2-year OS: 80.8% (95% CI 72.6–87.8) Toxicity: ⚠️ Grade ≥3 CRS: 6.1% ⚠️ Grade ≥3 ICANS: 14.7% 💀 2-year NRM: 5.4% Impact of Prior ICI Exposure: 🔽 Relapse risk lower: 21.7% vs 41.6% (p=0.03) 🔼 NRM higher: 11.7% vs 2.8% (p=0.03) ❌ No statistically significant PFS (p=0.19) or OS (p=0.26) difference Key Takeaway: CD19 CAR T achieves high, durable responses with low severe toxicity rates in PMBCL. Prior ICI may lower relapse risk but could increase NRM — an important balance to weigh in treatment planning. pubmed.ncbi.nlm.nih.gov/40785644/ #CAR_T #PMBCL #Lymphoma #CellTherapy #Oncology #Immunotherapy #HemeOncResearch



Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu



